<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225224</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-HV03</org_study_id>
    <nct_id>NCT01225224</nct_id>
  </id_info>
  <brief_title>Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers</brief_title>
  <official_title>Phase I Study of ASP015K: Single-Dose and Multiple-Dose Oral Administration in Healthy Nonelderly Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability and PK profiles of single and multiple doses of
      ASP015K in healthy nonelderly men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts; single and multiple administration parts. In single
      administration part, multiple dose levels of ASP015K or placebo are administered to Japanese
      and Caucasian men to evaluate whether there is ethnic differences in the pharmacokinetics and
      pharmacodynamics of ASK015K. In multiple administration part, drugs are administered only to
      Japanese volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2009</start_date>
  <completion_date type="Actual">March 10, 2010</completion_date>
  <primary_completion_date type="Actual">March 10, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluated by the incidence of AE, vital signs , standard 12-lead ECG and Laboratory tests</measure>
    <time_frame>For 48 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma unchanged drug concentration</measure>
    <time_frame>For 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary unchanged drug concentration</measure>
    <time_frame>For 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcription factor phosphorylation level</measure>
    <time_frame>For 48 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Pharmacokinetics of ASP015K</condition>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>ASP015K Single Japanese Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP015K Single Caucasian Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Japanese Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Caucasian Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP015K Multiple Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Multiple Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peficitinib</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP015K Multiple Group</arm_group_label>
    <arm_group_label>ASP015K Single Caucasian Group</arm_group_label>
    <arm_group_label>ASP015K Single Japanese Group</arm_group_label>
    <other_name>ASP015K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo Multiple Group</arm_group_label>
    <arm_group_label>Placebo Single Caucasian Group</arm_group_label>
    <arm_group_label>Placebo Single Japanese Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy judged by the investigator or subinvestigator on the basis of physical
             examination and all test results

          -  Weight

               -  Japanese: ≥ 50.0 kg to &lt; 80.0 kg

               -  Caucasians: ≥ 50.0 kg to &lt; 100.0 kg

          -  BMI

               -  Japanese: ≥ 17.6 kg/m2 to &lt; 26.4 kg/m2

               -  Caucasians: ≥ 18.0 kg/m2 to &lt; 30.0 kg/m2

          -  Written informed consent obtained from the subject personally

        Exclusion Criteria:

          -  Administered drug in another clinical study or a post-market clinical study in the 120
             days prior to the study

          -  Collection of 400 mL of whole blood within 90 days prior to the study,

             200 mL of whole blood within 30 days prior to the study or blood components within 14
             days prior to the study

          -  Received or is scheduled to receive drug treatment within 7 days prior to the drug
             administration

          -  A history of drug allergies

          -  Upper gastrointestinal symptoms, e.g., nausea, vomiting or stomachache, within 7 days
             prior to the drug admission

          -  Concurrent or previous liver disease, e.g., viral hepatitis or drug-induced hepatic
             injury

          -  Concurrent or previous heart disease, e.g., congestive heart failure, angina pectoris
             or arrhythmias requiring treatment

          -  Concurrent or previous kidney disease, e.g., acute renal failure,

        glomerulonephritis or interstitial nephritis (except for previous urinary

        calculus)

          -  Concurrent or previous cerebrovascular disease, e.g., cerebral infarction

          -  Concurrent or previous malignancy

          -  Concurrent or previous active or recurrent infection, e.g., hepatitis B,

        hepatitis C or syphilis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>Ethnic difference</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

